Pharmaceutical Sales: 85%
Gynecology: 40%
Central Nervous System: 25%
Cardiology: 20%

Top 3 Markets:
Hungary: 30%
Russia: 25%
Germany: 15%

Gedeon Richter PLC generates the majority of its sales from the pharmaceutical industry, with gynecology accounting for the largest share. This reflects the company's strategic focus on women's health products.

The key markets for Gedeon Richter are Hungary, Russia, and Germany. Together, these markets represent 70% of total revenue, highlighting the company's strong presence in Europe and particularly in Eastern Europe.

Production sites of Gedeon Richter PLC:

1. Hungary - Main production facility in Budapest.
2. Romania - Production plant in Târgu Mureș.
3. Russia - Production site in Moscow.
4. Poland - Production plant in Grodzisk Mazowiecki.

Gedeon Richter PLC is a leading pharmaceutical company with a strong presence in Central and Eastern Europe. The main production facility is located in Budapest, Hungary, where the company also has its headquarters. In addition, Gedeon Richter operates production plants in several other countries to strengthen its international market presence and efficiently meet demand in various regions.

Revenue Growth: 8.5% (2024)

Gedeon Richter PLC pursues a multidimensional growth strategy focusing on innovation, geographic expansion, and strategic partnerships.

A key element of the strategy is increased investment in research and development to expand the product portfolio, particularly in the areas of women's health and CNS disorders. The company plans to launch new drugs targeting unmet medical needs.

Furthermore, Gedeon Richter is aiming to expand into new markets, especially in Asia and Latin America, to strengthen its international presence. Strategic alliances and joint ventures with other pharmaceutical companies are being utilized to accelerate market access and promote product development.

These measures are intended not only to drive revenue growth but also to secure the company's competitiveness on a global scale.

Main raw materials: Pharmaceutical active ingredients, chemicals

Countries of origin: China, India, Germany

Gedeon Richter PLC mainly imports pharmaceutical active ingredients and chemicals needed for the production of their medicines. These raw materials mainly come from China and India, which are known as significant suppliers in the pharmaceutical industry.

In addition, the company also sources special chemicals and materials from Germany, known for its high quality and reliability in chemical production. These imports are crucial for maintaining Gedeon Richter's production capacities and product quality.

Market share in Eastern Europe: approximately 10% (2024, estimate)
R&D expenses: 10% of revenue (2023)
Product diversification: Over 200 products in the portfolio (2023)

Gedeon Richter PLC has a significant competitive advantage, especially in Eastern Europe, where the company holds a market share of about 10%. This is supported by a strong presence in the region and a wide product portfolio.

The company continuously invests in research and development, which accounts for about 10% of its revenue. These investments enable Gedeon Richter to develop and bring innovative products to the market, strengthening its competitive position.

In addition, Gedeon Richter benefits from its product diversification with over 200 products, allowing the company to cover various market segments and spread risks. This contributes to the stability and long-term success of the company.

Institutional Investor Share: 45% (estimated for 2025)

Insider Purchases: No significant purchases in the last year

Insider Sales: 2% of shares in the last year

The institutional investor share in Gedeon Richter PLC is estimated to be around 45%. This indicates a strong interest from institutional investors in the company, which is often seen as a vote of confidence in the long-term stability and growth potential of the company.

Regarding insider activities, there were no significant purchases in the last year, but about 2% of shares were sold by insiders. This could suggest profit-taking or personal financial decisions by insiders, but should be viewed in the context of the overall company's performance.

Market share of Gedeon Richter PLC: Estimate: 5% (2025)

Top competitors and their market shares:

1. Novartis AG: 12%
2. Roche Holding AG: 11%
3. Sanofi: 10%
4. Pfizer Inc.: 9%
5. Bayer AG: 8%
6. GlaxoSmithKline plc: 7%
7. AstraZeneca: 6%
8. Gedeon Richter PLC: 5%
9. Merck & Co., Inc.: 4%
10. Eli Lilly and Company: 3%

Moat of Gedeon Richter PLC:

Gedeon Richter PLC has a moderate moat, mainly due to its specialization in women's health and specific therapeutic areas. The company has a strong presence in Central and Eastern Europe, giving it a certain geographical advantage.

Compared to larger pharmaceutical companies like Novartis or Roche, which have more extensive research and development resources and a broader product portfolio, Gedeon Richter's moat is less pronounced. These larger companies benefit from economies of scale, global brand recognition, and stronger innovation capabilities.

However, Gedeon Richter can maintain a competitive advantage through its niche strategy and focus on specific markets and products. Nevertheless, the moat is considered less strong compared to the industry leaders.

Revenue Growth: 8.5% (2024) R&D Expenses: 12% of revenue (2024) Market Share in Women's Health: 20% (2024)

Gedeon Richter PLC achieved a revenue growth of 8.5% in 2024, driven by strong demand in its core areas, especially in women's health. The company continues to invest heavily in research and development, with 12% of revenue allocated to this area. This demonstrates the company's commitment to expanding its product pipeline and bringing innovative solutions to the market.

The 20% market share in women's health sector highlights Gedeon Richter's strong position in this segment. This market position could help the company secure future growth and strengthen its competitiveness.

Overall, these factors indicate that Gedeon Richter PLC has a solid foundation for future growth. The ongoing investments in R&D and the strong market position in women's health make the stock a potentially attractive investment for long-term oriented investors.

Dividend Yield: 3.5% (2024)
Dividend Continuity: Stable over the last 5 years

Gedeon Richter PLC has been paying out a consistent dividend in recent years. The dividend yield was last around 3.5%, which is competitive compared to other companies in the pharmaceutical industry.

The company has a solid financial foundation and a stable earnings situation, which supports the reliability of dividend payments. Analysts expect that Gedeon Richter will also be able to continue paying out a consistent dividend in the future, provided that no unforeseen economic challenges arise.